Longeveron to Present at the Emerging Growth Virtual Conference
Longeveron to Present at Emerging Growth Conference
MIAMI, FL (November 14, 2023) – Longeveron Inc., a clinical-stage biotechnology company developing cellular therapies for aging-related and other chronic diseases, announced today that it will be presenting at the Emerging Growth Conference on December 5, 2024.
The presentation, scheduled for 12:00 – 12:30 p.m. ET, will provide an overview of Longeveron’s innovative approach to treating age-related conditions using its proprietary mesenchymal stem cell platform.
“We are excited to share our progress with the investment community at the Emerging Growth Conference,” said [Insert Name and Title of Longeveron Representative]. “This is a valuable opportunity to highlight the potential of our therapies to address the growing need for effective treatments for age-related diseases.”
webcast Access and Q&A
The webcast for this conference presentation will be accessible through the “Events and Presentations” section of the Longeveron website. A replay will be available for 180 days following the event.
Interested parties can submit questions in advance to Questions@EmergingGrowth.com or ask them during the live presentation.
About Longeveron Inc.
Longeveron is a clinical-stage biotechnology company focused on developing cellular therapies for aging-related and other chronic diseases. The company’s proprietary platform utilizes mesenchymal stem cells (MSCs) to address a range of conditions, including Alzheimer’s disease, frailty, and acute respiratory distress syndrome.
Investor and Media Contact:
Derek Cole
Investor Relations Advisory Solutions
derek.cole@iradvisory.com
Longeveron too Showcase Groundbreaking Aging Therapies at Emerging Growth Conference
Miami, FL – Biopharmaceutical company Longeveron Inc. is poised to present its cutting-edge cell therapy platform at the Emerging Growth Conference on December 5, 2024.
The presentation,scheduled for 12:00-12:30 p.m. ET, will delve into Longeveron’s innovative approach to combating age-related diseases through its proprietary mesenchymal stem cell (MSC) technology.
“[Insert Name and Title of Longeveron Representative]” expressed strong enthusiasm for the opportunity, stating, “We are excited to share our progress with the investment community at the Emerging growth Conference.This platform allows us to highlight the potential of our therapies to address the growing need for effective treatments for age-related diseases.”
Accessibility and Engagement:
Investors and interested individuals can access the live webcast through the ”Events and presentations” section of the Longeveron website. A recording will be available for 180 days post-event.
Advance questions can be submitted to Questions@EmergingGrowth.com, or participants can engage in a live Q&A session during the presentation.
About Longeveron:
Longeveron Inc. is a clinical-stage biotech company dedicated to developing innovative cellular therapies for aging-related and chronic diseases. Leveraging its proprietary MSC platform, Longeveron is targeting a range of conditions including Alzheimer’s disease, frailty, and acute respiratory distress syndrome.